-
Mashup Score: 3
Tanto la AEMPS como la DG de Cartera y Farmacia del Ministerio coinciden en la necesidad de modificar esta herramienta como está concebida actualmente.
Source: elglobal.esCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 16IO Foundation Course - 12 day(s) ago
Discover the Interventional Oncology Foundation Course by CIRSE, a key opportunity for young interventionists exploring oncology treatments
Source: www.ecio.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3Program Guide – ASCO Meeting Program Guide - 15 day(s) ago
1 – 20 out of 5893 Results for “2024 ASCO Annual Meeting” 5893 Results Select All Presenter: Jens Hoeppner, FAChirg, FACS, MD Presenter: Christian U. Blank, MD, PhD Presenter: Suresh S. Ramalingam MD, FASCO, FACP Presenter: David undefined Spigel, FASCO, MD Presenter: Antonio Giordano MD, PhD Presenter: Sonia Pernas MD, PhD Presenter: Toshinari Yamashita, MD, PhD Presenter: Eva Maria Ciruelos MD, PhD Presenter: Fabrice Andre MD, PhD Presenter: Kevin Kalinsky MD, MS Presenter: Erin Frances Cobain, MD
Source: meetings.asco.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus pembrolizumab versus sunitinib comparison of CLEAR. Treatment-naïve patients with aRCC were randomly assigned to receive lenvatinib (20 mg orally once daily in 21-day cycles) plus pembrolizumab (200 mg intravenously once every 3 weeks) or sunitinib (50 mg orally once daily [4 weeks on/2
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate containing cytotoxic SN-38, the active metabolite of irinotecan. SG received a…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 7
Circulating-tumor DNA (ctDNA)-positive status was a negative prognostic biomarker in patients with muscle-invasive urothelial carcinoma after radical surgery and possibly a predictive biomarker for the overall survival benefit with adjuvant atezolizumab versus observation. The ctDNA-negative status possibly identified patients who experienced an unfavorable risk-benefit profile with adjuvant atezolizumab.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 4
It is not known whether molecular urothelial cancer (UC) subtypes change during metastatic evolution. Immunohistochemistry-based and histomorphological UC subtypes remain highly stable during metastasis. The luminal tumor cell differentiation of “stroma-rich” tumors based on immunohistochemical subtyping is apparently superimposed by desmoplastic tumor stroma content in transcriptome-based subtyping.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 9GUARD Consortium - investigación clínica - 2 month(s) ago
Una plataforma de investigación clínica y traslacional.
Source: guardconsortium.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 9GUARD Consortium - investigación clínica - 2 month(s) ago
Una plataforma de investigación clínica y traslacional.
Source: guardconsortium.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11Germline Exome Sequencing for Men with Testicular Germ Cell Tumor Reveals Coding Defects in Chromosomal Segregation and Protein-targeting Genes - 2 month(s) ago
This exome sequencing study of 293 men with familial or bilateral testicular germ cell tumor (TGCT) and 3157 cancer-free controls is the largest of its kind. Using a gene-agnostic approach, we identified germline coding changes associated with TGCT.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
El ‘fin’ de los IPT y el comienzo de un nuevo paradigma https://t.co/D0ZjirPFXp a través de @elglobales